ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)
Intrexon (NYSE: XON)
ZIOPHARM Oncology and Intrexon stocks gained heavily in early morning trading due to high trade volume. The companies announced that they would be working together to strengthen their oncology programs. Moving forward, the team will focus on novel chimeric antigen receptor T-cell, also known as CAR-T products in Germany. By moving ZIOP products into Germany through
Intrexon’s collaboration, both companies will share the upfront payment, royalties, and milestones equally.
What We’re Seeing In The Market Today
ZIOPHARM Oncology – ZIOPHARM Oncology stock saw sharp gains in early morning trading; climbing to $13.20 per share on heavy volume by 9:30. However, the early morning momentum has leveled off; leaving ZIOP with small gains so far today. Currently (12:24), the stock is trading at $11.70 per share after a gain of 2.27%.
Intrexon – Intrexon seems to have followed the same path as ZIOPHARM. By 9:30 heavy trade volume brought the price to $48.60 per share. After stabilizing, XON is currently (12:26) trading at $46.51 per share after a gain of 8.16% so far today.
What We Can Expect From ZIOP and XON Moving Forward
Both of these companies are incredibly strong players with room for growth. Their partnership in CAR-T products only makes them stronger. With that said, I think we can expect great long term growth out of both of them.
What Do You Think?
Where do you think ZIOP and XON are headed? Why? Let us know in the comments below!